267 related articles for article (PubMed ID: 28512699)
1. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Duchin K; Duggal A; Atiee GJ; Kidokoro M; Takatani T; Shipitofsky NL; He L; Zhang G; Kakkar T
Clin Pharmacokinet; 2018 Feb; 57(2):221-228. PubMed ID: 28512699
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube.
Moore KT; Krook MA; Vaidyanathan S; Sarich TC; Damaraju CV; Fields LE
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):321-7. PubMed ID: 27128839
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
[TBL] [Abstract][Full Text] [Related]
4. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects.
Song Y; Wang X; Perlstein I; Wang J; Badawy S; Frost C; LaCreta F
Clin Ther; 2015 Aug; 37(8):1703-12. PubMed ID: 26188837
[TBL] [Abstract][Full Text] [Related]
5. Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects.
Krishna G; Noveck R; Vargas R; Grasela D; Wang Z
Drugs R D; 2007; 8(1):43-50. PubMed ID: 17249848
[TBL] [Abstract][Full Text] [Related]
6. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers.
Burkhardt O; Stass H; Thuss U; Borner K; Welte T
Clin Pharmacokinet; 2005; 44(9):969-76. PubMed ID: 16122283
[TBL] [Abstract][Full Text] [Related]
7. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
[TBL] [Abstract][Full Text] [Related]
8. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intact.
McNeely EB; Talameh JA; Adams KF; Hull JH; Simmons B; Henry J; Brouwer KL; Patterson JH
Am J Health Syst Pharm; 2013 Jul; 70(14):1230-7. PubMed ID: 23820460
[TBL] [Abstract][Full Text] [Related]
10. A randomized, open-label 3-way crossover study to investigate the relative bioavailability and bioequivalence of crushed sildenafil 20 mg tablets mixed with apple sauce, extemporaneously prepared suspension (EP), and intact sildenafil 20 mg tablets in healthy volunteers under fasting conditions.
Gao X; Ndongo MN; Checchio TM; Cook J; Duncan B; LaBadie RR
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):74-80. PubMed ID: 27128005
[TBL] [Abstract][Full Text] [Related]
11. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
12. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
[TBL] [Abstract][Full Text] [Related]
13. An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers.
Teng R; Carlson G; Hsia J
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):182-9. PubMed ID: 25500486
[TBL] [Abstract][Full Text] [Related]
14. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule.
Parasrampuria DA; Kanamaru T; Connor A; Wilding I; Ogata K; Shimoto Y; Kunitada S
J Clin Pharmacol; 2015 Nov; 55(11):1286-92. PubMed ID: 25969414
[TBL] [Abstract][Full Text] [Related]
16. The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
Vincent J; Teng R; Pelletier SM; Willavize SA; Friedman HL
Am J Surg; 1998 Dec; 176(6A Suppl):23S-26S. PubMed ID: 9935253
[TBL] [Abstract][Full Text] [Related]
17. An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects.
Bui K; Birmingham B; Diva U; Berger B
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):420-427. PubMed ID: 28127938
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence and Pharmacokinetic Study of 2 Edoxaban Tablets in Healthy Chinese Subjects.
Liu L; Li X; Liu Y; Xu B; Li Y; Yuan F; Zhang P; Tu S; Hu W
Clin Pharmacol Drug Dev; 2022 Dec; 11(12):1440-1446. PubMed ID: 35950601
[TBL] [Abstract][Full Text] [Related]
19. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants.
Undre N; Dickinson J
BMJ Open; 2017 Apr; 7(4):e012252. PubMed ID: 28377389
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation - The Prospective KYU-RABLE Study.
Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Matsumoto T; Origasa H; Okumura K;
Circ J; 2019 Sep; 83(10):2017-2024. PubMed ID: 31511436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
